[go: up one dir, main page]

MX2016010266A - Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. - Google Patents

Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.

Info

Publication number
MX2016010266A
MX2016010266A MX2016010266A MX2016010266A MX2016010266A MX 2016010266 A MX2016010266 A MX 2016010266A MX 2016010266 A MX2016010266 A MX 2016010266A MX 2016010266 A MX2016010266 A MX 2016010266A MX 2016010266 A MX2016010266 A MX 2016010266A
Authority
MX
Mexico
Prior art keywords
cancer
dimethoxyquinolin
dicarboxamide
fluorophenyl
oxy
Prior art date
Application number
MX2016010266A
Other languages
English (en)
Other versions
MX384828B (es
Inventor
T Aftab Dana
Guz Nathan
Lau Stephen
HAMILL Noel
Walker Tracy
Galbraith Jana
Yau Simon
Shah Khalid
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2016010266A publication Critical patent/MX2016010266A/es
Publication of MX384828B publication Critical patent/MX384828B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevas formas sólidas cristalinas del compuesto químico N-{4-[(6,7- dimetoxiquinolin-4-il)oxi]feni1}-N'-(4- fluorofenil)ciclopropan-1, 1-dicarboxamida (Compuesto 1), y solvatos del mismo, que incluye hidratos, que son útiles para el tratamiento de cáncer. También se describen composiciones farmacéuticas que comprenden las formas sólidas cristalinas y procesos para elaborar las formas sólidas cristalinas, así como también métodos para usar las mismas para el tratamiento de cáncer, particularmente cáncer tiroideo, cáncer de próstata, cáncer hepatocelular, cáncer renal, y carcinoma de pulmón de células no pequeñas. Las formas sólidas cristalinas pueden ser usadas para hacer la sal de L-malato de cabozantinib.
MX2016010266A 2014-02-14 2015-02-16 Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. MX384828B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939985P 2014-02-14 2014-02-14
PCT/US2015/016052 WO2015123639A1 (en) 2014-02-14 2015-02-16 Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use

Publications (2)

Publication Number Publication Date
MX2016010266A true MX2016010266A (es) 2017-02-08
MX384828B MX384828B (es) 2025-03-14

Family

ID=52684662

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021001583A MX2021001583A (es) 2014-02-14 2015-02-16 Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
MX2016010266A MX384828B (es) 2014-02-14 2015-02-16 Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021001583A MX2021001583A (es) 2014-02-14 2015-02-16 Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.

Country Status (14)

Country Link
US (5) US10501418B2 (es)
EP (2) EP3105204A1 (es)
JP (2) JP6756617B2 (es)
KR (1) KR102354963B1 (es)
CN (1) CN106068255A (es)
AU (3) AU2015218236B2 (es)
BR (1) BR112016018450A2 (es)
CA (2) CA3181899A1 (es)
EA (1) EA032757B1 (es)
IL (1) IL247035B2 (es)
MX (2) MX2021001583A (es)
UA (1) UA123534C2 (es)
WO (1) WO2015123639A1 (es)
ZA (1) ZA201605424B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012013467A (es) 2010-05-20 2013-04-29 Array Biopharma Inc Compuestos macrociclicos como inhibidores de trk cinasa.
GEAP201913960A (en) 2013-03-15 2019-04-10 Exelixis Inc Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CA3181899A1 (en) 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US10159666B2 (en) 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
EP3551612A4 (en) * 2016-12-07 2020-08-12 MSN Laboratories Private Limited, R&D Center PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP7222895B2 (ja) * 2017-01-20 2023-02-15 エグゼリクシス， インコーポレイテッド がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP7166292B2 (ja) * 2017-05-26 2022-11-07 エグゼリクシス， インコーポレイテッド Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
EP3634413A1 (en) 2017-06-09 2020-04-15 Exelixis, Inc. Liquid dosage forms to treat cancer
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN107951850A (zh) * 2017-12-20 2018-04-24 深圳万乐药业有限公司 一种苹果酸卡博替尼片的制备方法
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
AU2019212801B2 (en) 2018-01-26 2024-07-04 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
MD3894012T2 (ro) 2018-12-13 2025-11-30 Exelixis Inc Forme cristaline și forme de sare ale unui inhibitor de kinază
WO2022115464A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
US11590122B2 (en) 2021-02-19 2023-02-28 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
EP1874759A4 (en) 2005-04-06 2009-07-15 Exelixis Inc C-MET MODULATORS MODULATORS AND METHODS OF USE
CN105106199A (zh) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
UY32142A (es) 2008-09-26 2010-05-31 Smithkline Beckman Corp Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
JP5486606B2 (ja) 2008-11-13 2014-05-07 エクセリクシス， インク． キノリン誘導体の調製方法
WO2010065838A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Methods of preparing quinoline derivatives
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
TW201118072A (en) 2009-07-17 2011-06-01 Exelixis Inc Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX2012010506A (es) 2010-03-12 2012-10-15 Exelixis Inc Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
PT2593090T (pt) 2010-07-16 2021-11-04 Exelixis Inc Composições farmacêuticas moduladoras de c-met
EP2621482A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CA2812744A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
FI2621481T4 (fi) 2010-09-27 2023-01-13 Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
JP2013543011A (ja) 2010-11-22 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌の治療法
AR085155A1 (es) 2011-02-10 2013-09-11 Exelixis Inc Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
WO2012151326A1 (en) 2011-05-02 2012-11-08 Exelixis, Inc. Method of treating cancer and bone cancer pain
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EA201490676A1 (ru) 2011-09-22 2015-02-27 Экселиксис, Инк. Способ лечения остеопороза
IN2014CN02971A (es) 2011-10-20 2015-07-03 Exelixis Inc
US9535315B2 (en) 2011-10-31 2017-01-03 Applied Materials, Inc. Method of fabricating a color filter array using a multilevel structure
EA201490946A1 (ru) 2011-11-08 2014-08-29 Экселиксис, Инк. Способ количественной оценки лечения рака
JP2014532766A (ja) 2011-11-08 2014-12-08 エクセリクシス， インク． 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
US20140121239A1 (en) 2012-09-07 2014-05-01 Exelixis, Inc. Method of treating lung adenocarcinoma
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
GEAP201913960A (en) 2013-03-15 2019-04-10 Exelixis Inc Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP2983639A1 (en) 2013-04-04 2016-02-17 Exelixis, Inc. Drug combinations to treat cancer
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CN104370811B (zh) * 2013-08-15 2019-02-12 广东东阳光药业有限公司 一种喹啉化合物的新晶型及其制备方法
CN103664778B (zh) * 2013-11-27 2017-04-05 苏州摩尔医药有限公司 一种抗肿瘤治疗药物卡博替尼的合成方法
CA3181899A1 (en) 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US10159666B2 (en) 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
US20170224670A1 (en) 2014-10-14 2017-08-10 Exelixis, Inc. Drug Combination to Treat Melanoma
JP7166292B2 (ja) * 2017-05-26 2022-11-07 エグゼリクシス， インコーポレイテッド Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法

Also Published As

Publication number Publication date
MX2021001583A (es) 2023-02-08
US10851061B2 (en) 2020-12-01
IL247035B (en) 2022-11-01
IL247035A0 (en) 2016-09-29
US20210198205A1 (en) 2021-07-01
JP6756617B2 (ja) 2020-09-16
US10501418B2 (en) 2019-12-10
BR112016018450A2 (pt) 2018-09-18
MX384828B (es) 2025-03-14
EP3738952A1 (en) 2020-11-18
WO2015123639A1 (en) 2015-08-20
EP3105204A1 (en) 2016-12-21
AU2015218236B2 (en) 2019-06-13
AU2021204278A1 (en) 2021-07-22
CA2939546A1 (en) 2015-08-20
ZA201605424B (en) 2022-12-21
US20230382867A1 (en) 2023-11-30
AU2019226302A1 (en) 2019-09-26
NZ723714A (en) 2021-03-26
US20170044106A1 (en) 2017-02-16
AU2019226302B2 (en) 2021-04-01
US11724986B2 (en) 2023-08-15
AU2015218236A1 (en) 2016-09-15
AU2021204278B2 (en) 2023-10-26
EA201691629A1 (ru) 2016-11-30
KR20160121544A (ko) 2016-10-19
US20200190033A1 (en) 2020-06-18
US11760726B2 (en) 2023-09-19
IL247035B2 (en) 2023-03-01
JP2017505796A (ja) 2017-02-23
EA032757B1 (ru) 2019-07-31
JP2019163337A (ja) 2019-09-26
US20210206722A1 (en) 2021-07-08
US12486233B2 (en) 2025-12-02
CA3181899A1 (en) 2015-08-20
CN106068255A (zh) 2016-11-02
CA2939546C (en) 2023-01-17
KR102354963B1 (ko) 2022-01-21
UA123534C2 (uk) 2021-04-21

Similar Documents

Publication Publication Date Title
MX2016010266A (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
JO3474B1 (ar) مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2019012505A (es) Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
TW201613864A (en) Novel compounds
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
TR201819805T4 (tr) Flavaglin türevleri̇.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EA201791671A1 (ru) 4-замещенные соединения бензоксаборола и их применение
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.